Today's PrEP research agenda seeks to clarify how to deliver what's available—and identify new strategies
PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables.
There are many moving pieces and many product types.
One key advocacy message is that no single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. We need to ensure that demonstration projects tell us how deliver what's available, and that research continues for additional options.
To learn more see:
- Past, current, and planned PrEP trials in AVAC's HIV Prevention Research and Development Database
- Ongoing and Planned PrEP Demonstration and Implementation Studies: A summary table including details on studies in Africa, Europe, Latin America and the United States
- Demanding Clarity on PrEP: Understanding recent data on oral PrEP — A March 2015 webinar with audio, slides and links to relevant CROI webcasts
- Introduction to Long-acting Injectables: An infographic detailing the process for developing long-acting injectables for PrEP and treatment
- AVAC Report 2014/15: Prevention on the Line — Read an excerpt from our latest report, "Invest in an oral PrEP-driven paradigm shift".